Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?-Reference-Cited by-同舟云学术

Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?

Published:2016-01-11 Issue:3 Volume:91 Page:277-282
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Campuzano-Zuluaga Germán¹,Deutsch Yehuda²,Salzberg Matthew²,Gomez Alexandra²,Vargas Fernando²,Elias Roy²,Kwon Deukwoo³,Goodman Mark²,Ikpatt Offiong F.¹,Chapman Jennifer R.¹,Watts Justin²,Vega Francisco¹,Swords Ronan²

Affiliation:

1. Division of Hematopathology; Department of Pathology and Laboratory Medicine; University of Miami and Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospital; Miami Florida

2. Division of Hematology and Oncology; Department of Medicine; University of Miami and Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospital; Miami Florida

3. Sylvester Comprehensive Cancer Center, University of Miami; Miami Florida

Funder

The National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities

Paps Corps Endowed Chair in Leukemia and the Miami Clinical and Translational Science Institute (CTSI)

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24271/fullpdf

Reference30 articles.

1. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial;Kern;Blood,2003